High Intensity Intervallic Training in Children With Bronchiolitis

Status Recruiting

Clinical Trial Summary

Post-Infectious Bronchiolitis Obliterans (PIBO) is an irreversible obstructive lung disease characterized by subepithelial inflammation and fibrotic narrowing of the bronchioles after lower respiratory tract infection. This disease is diagnosed mainly in children, more frequently before the age of 2 years. Due to symptoms such as dry cough and dyspnea sensation, most of these patients have low levels of physical activity compared to healthy individuals. Physical activity can positively influence oxygen consumption, muscle strength, and quality of life. High levels of oxygen consumption are associated with a lower risk of respiratory disease and hospitalization. High-intensity interval training (HIIT) may be an effective way to improve oxygen consumption, muscle strength, and quality of life in patients with chronic diseases. HIIT has been shown to produce less dyspnea sensation and to be more entertaining in children and adolescents with respiratory disease compared to continuous training. Thus, the investigators propose to perform telematically real-time guided training to reduce travel times and additional costs to patients. Objective: To analyze the effects of a telematically supervised high-intensity intervallic training program on aerobic fitness, as well as functional/clinical outcomes in patients with PIBO. Methods: Randomized controlled trial with two groups. Exercise group: 16-week HIIT training conducted telematically; Control group: will follow the routine physician's recommendations. Patients will be recruited at both Vall D'Hebrón University Hospital (Barcelona) and Niño Jesús University Hospital (Madrid). Criteria for participation: (I) Diagnosis of PIBO; (II) Clinically stable at the time of the assessments; (III) Age between 6 to 20 years old.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Bronchiolitis
Bronchiolitis Obliterans
Bronchiolitis Obliterans Syndrome

Clinical Trial Details

NCT number	NCT05881538
Study type	Interventional
Source	Universitat Internacional de Catalunya
Contact	Márcio VF Donadio, PhD
Phone	+34 93 504 20 00
Email	mdonadio@uic.es
Status	Recruiting
Phase	N/A
Start date	May 29, 2023
Completion date	September 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03603899` - Hp129 Xenon Imaging and BOS in Lung Transplantation	Phase 1/Phase 2
Recruiting	`NCT04098445` - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Completed	`NCT02441413` - Transplant Optimization Using Functional Imaging (TROFI)	N/A
Recruiting	`NCT02543073` - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT	Phase 1/Phase 2
Terminated	`NCT01432080` - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant	Phase 2
Recruiting	`NCT00163696` - Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease	N/A
Completed	`NCT00029328` - Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation	Phase 1/Phase 2
Terminated	`NCT01163786` - A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD	Phase 2
Recruiting	`NCT02627833` - Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO	N/A
Completed	`NCT01212406` - Vitamin D in Bronchiolitis Obliterans Syndrome	Phase 4
Completed	`NCT01211509` - Montelukast in Bronchiolitis Obliterans Syndrome	Phase 4
Completed	`NCT00701922` - Surveillance Study of Viral Infections Following Lung Transplantation	N/A
Completed	`NCT00141726` - Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant	Phase 2
Terminated	`NCT04655508` - Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation	Phase 3
Withdrawn	`NCT02109237` - Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3	N/A
Completed	`NCT01327248` - Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans	N/A
Recruiting	`NCT05932316` - Evaluating Bronchodilator Response in Patients With Bronchiectasis	N/A
Active, not recruiting	`NCT03656926` - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)	Phase 3
Terminated	`NCT01327625` - Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans	N/A
Completed	`NCT01206309` - Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

High Intensity Intervallic Training in Children With Bronchiolitis Obliterans — PIBOHIIT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms